S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Biden signs bill extending a key US surveillance program after divisions nearly forced it to lapse
MarketBeat Week in Review – 4/15 - 4/19
The drug war devastated Black and other minority communities. Is marijuana legalization helping?
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
A man escaped Sudan's bloody civil war. His mysterious death in Missisippi has sparked suspicion
Record Store Day celebrates indie retail music sellers as they ride vinyl's popularity wave
Panama Papers trial's public portion comes to an unexpectedly speedy end
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Biden signs bill extending a key US surveillance program after divisions nearly forced it to lapse
MarketBeat Week in Review – 4/15 - 4/19
The drug war devastated Black and other minority communities. Is marijuana legalization helping?
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
A man escaped Sudan's bloody civil war. His mysterious death in Missisippi has sparked suspicion
Record Store Day celebrates indie retail music sellers as they ride vinyl's popularity wave
Panama Papers trial's public portion comes to an unexpectedly speedy end
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Biden signs bill extending a key US surveillance program after divisions nearly forced it to lapse
MarketBeat Week in Review – 4/15 - 4/19
The drug war devastated Black and other minority communities. Is marijuana legalization helping?
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
A man escaped Sudan's bloody civil war. His mysterious death in Missisippi has sparked suspicion
Record Store Day celebrates indie retail music sellers as they ride vinyl's popularity wave
Panama Papers trial's public portion comes to an unexpectedly speedy end
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Biden signs bill extending a key US surveillance program after divisions nearly forced it to lapse
MarketBeat Week in Review – 4/15 - 4/19
The drug war devastated Black and other minority communities. Is marijuana legalization helping?
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
A man escaped Sudan's bloody civil war. His mysterious death in Missisippi has sparked suspicion
Record Store Day celebrates indie retail music sellers as they ride vinyl's popularity wave
Panama Papers trial's public portion comes to an unexpectedly speedy end
NASDAQ:CDTX

Cidara Therapeutics (CDTX) Stock Price, News & Analysis

$0.68
-0.04 (-5.55%)
(As of 04/19/2024 ET)
Today's Range
$0.68
$0.74
50-Day Range
$0.64
$1.16
52-Week Range
$0.59
$1.48
Volume
364,913 shs
Average Volume
1.05 million shs
Market Capitalization
$61.71 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.67

Cidara Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
585.3% Upside
$4.67 Price Target
Short Interest
Healthy
0.22% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.85
Upright™ Environmental Score
News Sentiment
0.33mentions of Cidara Therapeutics in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$40,490 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($0.28) to ($0.65) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.59 out of 5 stars

Medical Sector

255th out of 909 stocks

Biological Products, Except Diagnostic Industry

37th out of 151 stocks

CDTX stock logo

About Cidara Therapeutics Stock (NASDAQ:CDTX)

Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also advances its Cloudbreak platform to develop conjugates for the prevention and treatment of influenza and other viral infections, such as RSV, HIV, and the SARS-CoV-2 strains causing COVID-19. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.

CDTX Stock Price History

CDTX Stock News Headlines

CDTX Cidara Therapeutics, Inc.
SHOCKING Crypto Leak…
A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.
Cidara Therapeutics, Inc. (CDTX)
Cidara Therapeutics, Inc.
SHOCKING Crypto Leak…
A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.
Cidara Therapeutics Granted Nasdaq Listing Extension
See More Headlines
Receive CDTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cidara Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/10/2021
Today
4/20/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:CDTX
Fax
N/A
Employees
73
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$4.67
High Stock Price Target
$6.00
Low Stock Price Target
$3.00
Potential Upside/Downside
+585.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-29,800,000.00
Pretax Margin
-53.14%

Debt

Sales & Book Value

Annual Sales
$64.29 million
Book Value
($0.04) per share

Miscellaneous

Free Float
83,886,000
Market Cap
$61.71 million
Optionable
Optionable
Beta
0.98
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

  • Dr. Jeffrey L. Stein Ph.D. (Age 69)
    President, CEO & Executive Director
    Comp: $873.25k
  • Dr. Preetam Shah M.B.A. (Age 51)
    Ph.D., CFO, Chief Business Officer & Principal Accounting Officer
    Comp: $577.85k
  • Dr. Taylor Sandison (Age 52)
    Chief Medical Officer
    Comp: $632.05k
  • Dr. Kevin M. Forrest Ph.D. (Age 47)
    Founder and Chief Strategy Officer
    Comp: $333.31k
  • Mr. Shane M. Ward (Age 49)
    COO & Chief Legal Officer
  • Ms. Allison Lewis CCP
    SPHR, Senior Vice President of People & Culture
  • Dr. Leslie Tari Ph.D. (Age 57)
    Chief Scientific Officer
    Comp: $845.1k
  • Ms. Laura A. Navalta
    Senior Vice President of Clinical Operations
  • Dr. Nicole Davarpanah J.D.
    M.D., Senior VP of Translational Research & Development

CDTX Stock Analysis - Frequently Asked Questions

Should I buy or sell Cidara Therapeutics stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cidara Therapeutics in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CDTX shares.
View CDTX analyst ratings
or view top-rated stocks.

What is Cidara Therapeutics' stock price target for 2024?

3 brokers have issued 12 month price targets for Cidara Therapeutics' stock. Their CDTX share price targets range from $3.00 to $6.00. On average, they predict the company's stock price to reach $4.67 in the next year. This suggests a possible upside of 585.3% from the stock's current price.
View analysts price targets for CDTX
or view top-rated stocks among Wall Street analysts.

How have CDTX shares performed in 2024?

Cidara Therapeutics' stock was trading at $0.7940 at the beginning of the year. Since then, CDTX shares have decreased by 14.2% and is now trading at $0.6810.
View the best growth stocks for 2024 here
.

Are investors shorting Cidara Therapeutics?

Cidara Therapeutics saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 195,400 shares, an increase of 8.9% from the March 15th total of 179,500 shares. Based on an average daily volume of 671,800 shares, the short-interest ratio is presently 0.3 days.
View Cidara Therapeutics' Short Interest
.

When is Cidara Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our CDTX earnings forecast
.

How were Cidara Therapeutics' earnings last quarter?

Cidara Therapeutics, Inc. (NASDAQ:CDTX) posted its quarterly earnings results on Wednesday, November, 10th. The biotechnology company reported ($0.37) EPS for the quarter, missing analysts' consensus estimates of ($0.36) by $0.01. The biotechnology company earned $7.08 million during the quarter, compared to the consensus estimate of $3.62 million. Cidara Therapeutics had a negative trailing twelve-month return on equity of 264.84% and a negative net margin of 55.49%.

What other stocks do shareholders of Cidara Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cidara Therapeutics investors own include Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Verastem (VSTM), Dynavax Technologies (DVAX), Micron Technology (MU), Exelixis (EXEL), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE) and Catalyst Pharmaceuticals (CPRX).

When did Cidara Therapeutics IPO?

Cidara Therapeutics (CDTX) raised $60 million in an initial public offering (IPO) on Wednesday, April 15th 2015. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Jefferies and Leerink Partners acted as the underwriters for the IPO and Wedbush PacGrow Life Sciences, Needham and BTIG were co-managers.

How do I buy shares of Cidara Therapeutics?

Shares of CDTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CDTX) was last updated on 4/20/2024 by MarketBeat.com Staff

From Our Partners